AzTrials
AzTrials

ObesityMHONCT06032312

Metabolically Healthy Obese

An observational study of Obesity and Metabolic Syndrome, run by Tel-Aviv Sourasky Medical Center at 1 site in Israel.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Little is known about the associated factors and mechanisms involved in the development of metabolic disturbance in pediatric obesity. The overall objective of the present study is to investigate clinical, anthropometric, socio-demographic and lifestyle predictors of MHO among obese children and adolescents. Read more about this study

Who is it for?
Ages 10 to 18 years
Conditions the study is for
Obesity, Metabolic Syndrome
What is being tested?
description
How many people
60 participants
Where
1 siteIsrael
Study dates
1 Dec 2020to 1 Jan 2025
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 10 to 18 years
  • All sexes
  • Child, Adult

Study population: The study will be performed in the Nutrition and Obesity Clinic of the Pediatric Gastroenterology Unit at "Dana Dwek" Children's Hospital. All children and adolescents that will be admitted to our clinic between December 2020 and December 2024 will be included in the study.

Who may be able to join

  • Children aged 10-18 with obesity
  • Attendance of the obesity clinic in the pediatric gastroenterology unit at "Dana-Dwek" children's hospital, Tel Aviv Sourasky Medical Center.

Who cannot join

  • Children with congenital or acquired heart disease
  • Children with inflammatory conditions
  • Children with neurological conditions that affect body composition

Trial locations and contacts

1 site in 1 country.

Hadar Moran Lev, MD contact

972527360713

hadarlev6@gmail.com

Israel1 site, 1 recruiting
  • Tel Aviv medical center

    Tel Aviv

    Hadar Moran Lev, MD, 972527360713

    Recruiting

Other trials in Israel

About this study

Official title: Phenotyping Metabolically Healthy Obese Adolescents

Little is known about the associated factors and mechanisms involved in the development of metabolic disturbance in pediatric obesity. The overall objective of the present study is to investigate clinical, anthropometric, socio-demographic and lifestyle predictors of MHO among obese children and adolescents. The Aim of the present study is to investigate the effect of fat distribution, muscle mass, strength and physical activity level on metabolic morbidity in obese adolescents.

Read the detailed description

The global epidemic of childhood obesity and the accompanying rise in the prevalence of endocrine, metabolic, and cardiovascular comorbidities among the youth represents one of the most important public health issues of the modern world. The earlier occurrence and increase in the prevalence of both pediatric obesity and metabolic syndrome (MS) lead to a potential decline in life expectancy such that the youth of today could be the first generation to live shorter lives than their parents.

In the context of the childhood obesity pandemic, a distinct subgroup of obese youth who are less prone to the development of metabolic disturbances, termed "metabolically healthy obese" (MHO), has recently been characterized. Despite their obese state, MHO individuals display a "favorable" metabolic profile, with preserved insulin sensitivity, normal BP and glucose regulation, normal lipid and liver enzyme levels, as well as a normal hormonal, inflammation and immune profile. Although the MHO status might not necessarily translate into lower mortality and can evolve into "metabolically unhealthy obese" (MUO) phenotype during puberty, defining the MHO subpopulation among obese youth is critically important in order to elucidate the mechanisms protecting against the clustering of cardiometabolic risk factors, and their implications on clinical, preventive, and therapeutic decision-making.

Only few studies have evaluated predictors and risk factors for MUO, and they were based on a variety of definitions of MHO and the criteria used for defining it. Moreover, little is known about the mechanisms of the development of metabolic disturbances in pediatric obesity. More data are needed in order to identify the parameters most capable of predicting clinically significant outcomes. In this research, the researchers aim to investigate socio-demographic, clinical, anthropometric, physiological, and lifestyle predictors of MHO.

Aim:

  1. To investigate socio-demographic, clinical, anthropometric, and lifestyle predictors for MHO.
  2. To investigate the interaction between fat mass and distribution, muscle mass and strength and physical activity level on metabolic morbidity in obese adolescents.
  3. To investigate the association between MHO predictors and metabolic disturbances.

Study design:

  1. Patient Population This prospective observational, cross-sectional study will be performed in the Nutrition and Obesity Clinic of the Pediatric Gastroenterology Unit at "Dana Dwek" Children's Hospital and at the "Gepner Lab" at the Sackler Faculty of Medicine.

Fifteen obese adolescents (age 12-18 years, body mass index [BMI] >95th percentile) without metabolic risk factors and fifteen obese adolescents (matched for BMI z-score, sex and age) with 1 or more components of the metabolic syndrome will be recruited.

Exclusion criteria: Adolescents with background diseases or past/current treatment with medications that may influence body composition or metabolic risk (e.g., inflammatory conditions).

2 Data Collection

The information that will be obtained from the medical files will include:

  1. Sociodemographic characteristics: sex, ethnicity, home address, number of children in the family, household (single parent/two parent), parents' level of education.
  2. Medical history: perinatal characteristics (pregnancy, birth weight, gestational age, feeding practice during the first year of life), age of adiposity rebound, medications, menses (regular/irregular/oral contraceptives), sleep habits and family history of cardiometabolic diseases (diabetes, hypertension, dyslipidemia, cardiovascular disease, and cerebrovascular episodes) in first- and second-degree relatives.
  3. The obese children's perceptions of their motivation, health and social status will be scored on a 1-10 scale and recorded at admission to the clinic.

All participants will undergo a clinical evaluation that includes a physical examination, systolic and diastolic BP and anthropometric measurements (height, weight, and calculated BMI).

CLINICAL AND METABOLIC ASSESSMENT Weight and height will be measured according to standardized protocols. BMI percentiles will be computed by means of sex- and age- specific BMI reference values from the Center for Disease Control and Prevention growth charts. Body composition will be assessed with bioelectrical impedance. Laboratory and radiologic parameters will include a liver enzyme profile, a lipid profile, glucose, insulin, HbA1c, and C-reactive protein levels, and abdominal ultrasonography. The participants will be referred for pelvic ultrasonography, polysomnography or an ophthalmologic evaluation if clinically indicated.

NUTRITIONAL ASSESSMENT The nutritional assessment will be based on an FFQ food report administered by a registered dietician at study entry.

BODY COMPOSITION ASSESSMENT

  1. Lean body mass and fat mass will be calculated by bioelectrical impedance analysis by means of a multi-frequency SECA (mBCA 514 Medical) body composition analyzer. The participants will be required to wear light clothing during the body composition assessments and remove all jewelry, shoes, and socks. Measurements will be conducted in the morning following an overnight fast.
  2. Abdominal adipose tissue distribution and liver fat will be assessed by MRI and MRS. Muscle function and physical activity Muscle strength and function will be measured by a handgrip dynanometer. The participants will be asked to wear an accelerometer for 7 days in order to measure their levels of physical activity and sleep habits.
  3. Definition of Study Variables Ethnicity will be defined as the birthplace of the parents or grandparents (if the parents were born in Israel) and categorized according to country of origin. Socioeconomic position will be determined by the patient's home address according to the Israel Central Bureau of Statistics' Characterization and Classification of Statistical Areas within Municipalities and Local Councils by the Socio-Economic Level of the Population 2015
Being tested
description
Medical subject headings
Obesity, Metabolic Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • descriptionOther

    no intervention, just description of the groups

Study groups in NCT06032312
Study groupRoleWhat they receive
1metabolic healthy obese
Receives: Other: description
2metabolic unhealthy obese
Receives: Other: description

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Body composition (fat and fat free mass) of MHO

    body fat and fat free mass of MHO will be assessed by bioelectrical impedance

    Measured: 1 day

  2. Abdominal fat distribution using abdominal MRI

    Abdominal fat distribution will be assessed by abdominal MRI. a researchers will calculate the visceral and sub-cutanic fat volume

    Measured: 3 days

  3. Dietary pattern in MHO

    Dietary pattern will be assessed by food frequency questioner that will asses consumption of dietary items (from once a day to less than once a month or never)

    Measured: 1 day

  4. physical activity of MHO

    physical activity be assessed by acetometer that will a measure walk distance per day

    Measured: 3 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Sep 2023
  2. Study start1 Dec 2020
  3. Primary completion1 Dec 2024 (estimated)
  4. Study completion1 Jan 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06032312
Sponsor's protocol ID
0799-20-TLV
Acronym
MHO
Status last verified
Sep 2023
First submitted
18 Jul 2023
Last updated
13 Sep 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: No Data will be shared by other researchers

Publications

  • Moran-Lev H, Sternfeld R, Lazmi R, Ohayon R, Dudi R, Brener A, Sagi SZ, Cohen S, Lubetzky R, Gepner Y. Hepatic fat and dietary intake as determinants of metabolic health in obese adolescents: a cross-sectional MRI study. Front Nutr. 2025 Jul 9;12:1559271. doi: 10.3389/fnut.2025.1559271. eCollection 2025.

    PubMed 40704318

Questions about this trial

What is this clinical trial studying?

An observational study of Obesity and Metabolic Syndrome, run by Tel-Aviv Sourasky Medical Center at 1 site in Israel.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 13 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Hadar Moran Lev, MD (972527360713, hadarlev6@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Body composition (fat and fat free mass) of MHO (time frame: 1 day). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06032312, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Sep 2023.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in